![Page 1: PCI Pharmaceutical Consulting - IFFiff.nu/_files/qprole/qproleday2101115.pdfPCI Pharmaceutical Consulting . ... •MHRA Compliance Report program and FDA ... probably get into an OOS](https://reader034.vdocuments.us/reader034/viewer/2022051407/5b0b13057f8b9aba628d41b6/html5/thumbnails/1.jpg)
The Role of the QP: before & after Annex 16
Presented by: Karen Ginsbury
For IFF, Denmark
November 2015
PCI Pharmaceutical Consulting
![Page 2: PCI Pharmaceutical Consulting - IFFiff.nu/_files/qprole/qproleday2101115.pdfPCI Pharmaceutical Consulting . ... •MHRA Compliance Report program and FDA ... probably get into an OOS](https://reader034.vdocuments.us/reader034/viewer/2022051407/5b0b13057f8b9aba628d41b6/html5/thumbnails/2.jpg)
What’s bothering me…
• Getting geared up to do cleaning validation using the PDE / HBEL toxicological limits
• Getting a handle on the CMO supply chain –managing outsourced operations
![Page 3: PCI Pharmaceutical Consulting - IFFiff.nu/_files/qprole/qproleday2101115.pdfPCI Pharmaceutical Consulting . ... •MHRA Compliance Report program and FDA ... probably get into an OOS](https://reader034.vdocuments.us/reader034/viewer/2022051407/5b0b13057f8b9aba628d41b6/html5/thumbnails/3.jpg)
Responsibility Authority
• (Duty and that Is to release the batches)
• (Gives you a right to decide on the status of the batch including to reject the batch)
![Page 4: PCI Pharmaceutical Consulting - IFFiff.nu/_files/qprole/qproleday2101115.pdfPCI Pharmaceutical Consulting . ... •MHRA Compliance Report program and FDA ... probably get into an OOS](https://reader034.vdocuments.us/reader034/viewer/2022051407/5b0b13057f8b9aba628d41b6/html5/thumbnails/4.jpg)
Responsibility Authority
• Having the duty to perform a task
• Being accountable for performing that task
• Having control over the performance of the task
• Without “additional” authorization
• The power or right to give orders, make decisions, and enforce obedience
• Within the framework of a company or organization
![Page 5: PCI Pharmaceutical Consulting - IFFiff.nu/_files/qprole/qproleday2101115.pdfPCI Pharmaceutical Consulting . ... •MHRA Compliance Report program and FDA ... probably get into an OOS](https://reader034.vdocuments.us/reader034/viewer/2022051407/5b0b13057f8b9aba628d41b6/html5/thumbnails/5.jpg)
Responsibility Authority
• YOUR duty to:
– Keep management informed
– Request and insist on appropriate resources
– Take action if authority is not granted
• must be granted by:
– Owner
– Board of directors
– General manager / CEO…
– Your boss if other than the above
• AND they must allow you to perform your responsibilities without interference and with appropriate resources
![Page 6: PCI Pharmaceutical Consulting - IFFiff.nu/_files/qprole/qproleday2101115.pdfPCI Pharmaceutical Consulting . ... •MHRA Compliance Report program and FDA ... probably get into an OOS](https://reader034.vdocuments.us/reader034/viewer/2022051407/5b0b13057f8b9aba628d41b6/html5/thumbnails/6.jpg)
Responsibility vs Authority
![Page 7: PCI Pharmaceutical Consulting - IFFiff.nu/_files/qprole/qproleday2101115.pdfPCI Pharmaceutical Consulting . ... •MHRA Compliance Report program and FDA ... probably get into an OOS](https://reader034.vdocuments.us/reader034/viewer/2022051407/5b0b13057f8b9aba628d41b6/html5/thumbnails/7.jpg)
• The behaviors, beliefs and values characteristic of a particular group
• Culture is:– Transmitted actively by defining:
• Mission
• Goals
• Metrics
– Transmitted passively and often subconsciously by behavior, body language, facial expressions and other actions
![Page 8: PCI Pharmaceutical Consulting - IFFiff.nu/_files/qprole/qproleday2101115.pdfPCI Pharmaceutical Consulting . ... •MHRA Compliance Report program and FDA ... probably get into an OOS](https://reader034.vdocuments.us/reader034/viewer/2022051407/5b0b13057f8b9aba628d41b6/html5/thumbnails/8.jpg)
Delegated QP with Head QP
• What happens if you disagree with the Head QP who overturns your decision?
• The final responsibility is with the Head QP and they could overturn and sign
• Document all the information that is the basis for your decision and the Head QP then must document their reason for overturning your recommendation
• This should be in the SOP itself. Some companies put in that batch rejection must run by or be performed by the Head QP
![Page 9: PCI Pharmaceutical Consulting - IFFiff.nu/_files/qprole/qproleday2101115.pdfPCI Pharmaceutical Consulting . ... •MHRA Compliance Report program and FDA ... probably get into an OOS](https://reader034.vdocuments.us/reader034/viewer/2022051407/5b0b13057f8b9aba628d41b6/html5/thumbnails/9.jpg)
Better do it now…
• Qualitycustomer requirements expectationsfulfilling specificationsconsistently producing the same product which is the one you intend to produce
• Quality is meeting all the requirements all the time
• Quality Systemensures or is intended to ensure that we achieve qualityawarenessSOPs documents explaining how to do activities and implement regulatory requirements and guidelines
• Is the sum total of the organized arrangements (facility, utility, systems, equipment design, activities, procedures, personnel…) made with the intention of preventing things from going wrong and ensuring that the process and the product meet all the requirements all the time
![Page 10: PCI Pharmaceutical Consulting - IFFiff.nu/_files/qprole/qproleday2101115.pdfPCI Pharmaceutical Consulting . ... •MHRA Compliance Report program and FDA ... probably get into an OOS](https://reader034.vdocuments.us/reader034/viewer/2022051407/5b0b13057f8b9aba628d41b6/html5/thumbnails/10.jpg)
What sort of Organization do you work in / with? – active and visible support
![Page 11: PCI Pharmaceutical Consulting - IFFiff.nu/_files/qprole/qproleday2101115.pdfPCI Pharmaceutical Consulting . ... •MHRA Compliance Report program and FDA ... probably get into an OOS](https://reader034.vdocuments.us/reader034/viewer/2022051407/5b0b13057f8b9aba628d41b6/html5/thumbnails/11.jpg)
Grumpy Cat
• What has changed?
• What is your most challenging issue?
![Page 12: PCI Pharmaceutical Consulting - IFFiff.nu/_files/qprole/qproleday2101115.pdfPCI Pharmaceutical Consulting . ... •MHRA Compliance Report program and FDA ... probably get into an OOS](https://reader034.vdocuments.us/reader034/viewer/2022051407/5b0b13057f8b9aba628d41b6/html5/thumbnails/12.jpg)
What’s Troubling Me…
![Page 13: PCI Pharmaceutical Consulting - IFFiff.nu/_files/qprole/qproleday2101115.pdfPCI Pharmaceutical Consulting . ... •MHRA Compliance Report program and FDA ... probably get into an OOS](https://reader034.vdocuments.us/reader034/viewer/2022051407/5b0b13057f8b9aba628d41b6/html5/thumbnails/13.jpg)
Certification by a QP and Batch Release: Annex 16
• Issued October 2015
• Effective 15 APRIL, 2016
• Reason for update: SUPPLY CHAIN
![Page 14: PCI Pharmaceutical Consulting - IFFiff.nu/_files/qprole/qproleday2101115.pdfPCI Pharmaceutical Consulting . ... •MHRA Compliance Report program and FDA ... probably get into an OOS](https://reader034.vdocuments.us/reader034/viewer/2022051407/5b0b13057f8b9aba628d41b6/html5/thumbnails/14.jpg)
Let’s look at Annex 16What jumps out ?
• 8 has grown to 21• Control of entire supply chain including excipients and API
and need to know the whole chain – if not in full control need agreements with QPs preceding you before release of the final productis a major oversight
• Need confidence in the whole system – can only get the oversight if you have set up a working system which makes the information available – will need a lot of ongoing effort:RESOURCES for setting up the system to get the data / information and then for maintaining the system and handling changes - education
![Page 15: PCI Pharmaceutical Consulting - IFFiff.nu/_files/qprole/qproleday2101115.pdfPCI Pharmaceutical Consulting . ... •MHRA Compliance Report program and FDA ... probably get into an OOS](https://reader034.vdocuments.us/reader034/viewer/2022051407/5b0b13057f8b9aba628d41b6/html5/thumbnails/15.jpg)
Let’s look at Annex 16What jumps out ?
• Prepare end to end process maps – block diagrams showing every link in the supply chain back to earliest starting materials and through to the other end i.e. distribution
• Make a risk assessment on the whole supply chain and justify what you have or don’t have – can we have “white list” suppliers
• Put your resources at the high risk items
![Page 16: PCI Pharmaceutical Consulting - IFFiff.nu/_files/qprole/qproleday2101115.pdfPCI Pharmaceutical Consulting . ... •MHRA Compliance Report program and FDA ... probably get into an OOS](https://reader034.vdocuments.us/reader034/viewer/2022051407/5b0b13057f8b9aba628d41b6/html5/thumbnails/16.jpg)
Let’s look at Annex 16What jumps out ?
• Manufacturing steps at different sites – quality agreement and CLEAR definition as to which QP is responsible for what operations
• Handling of unexpected deviationsQP discretion? Yes or no
![Page 17: PCI Pharmaceutical Consulting - IFFiff.nu/_files/qprole/qproleday2101115.pdfPCI Pharmaceutical Consulting . ... •MHRA Compliance Report program and FDA ... probably get into an OOS](https://reader034.vdocuments.us/reader034/viewer/2022051407/5b0b13057f8b9aba628d41b6/html5/thumbnails/17.jpg)
Annex 16
• Potential product quality defects are included and chapter 8 gets a mention – if PV QP doesn’t share information about post-marketing events…how will the batch release QP know if there are potential quality defects
• Monthly meetings between PV QP and release QP to share adverse events defined in SOPoutsourced PV so have SOP and quality agreement to share everything that is received post market from the market twice a year and if a signal is identified
• We apparently need a contract or SOP between QP release and QP PV regarding who takes action when product hold / recall is warranted – who makes that decision – either one could make the decision but must notify the other
![Page 18: PCI Pharmaceutical Consulting - IFFiff.nu/_files/qprole/qproleday2101115.pdfPCI Pharmaceutical Consulting . ... •MHRA Compliance Report program and FDA ... probably get into an OOS](https://reader034.vdocuments.us/reader034/viewer/2022051407/5b0b13057f8b9aba628d41b6/html5/thumbnails/18.jpg)
Annex 16Batch release – pre-requisites
• Supplier qualification and falsified medicines directive
• API and excipients:– Audits
– quality agreements
• CMOs:– Production
– Packaging
– Other service providers…
![Page 19: PCI Pharmaceutical Consulting - IFFiff.nu/_files/qprole/qproleday2101115.pdfPCI Pharmaceutical Consulting . ... •MHRA Compliance Report program and FDA ... probably get into an OOS](https://reader034.vdocuments.us/reader034/viewer/2022051407/5b0b13057f8b9aba628d41b6/html5/thumbnails/19.jpg)
Annex 16Batch release – pre-requisites
• Validation and qualification (annex 15)in – or out of scope?
• Computerized systems (annex 11)especially for batch release and inventoryin – or out of scope?
• Batch record review and data integrity…
![Page 20: PCI Pharmaceutical Consulting - IFFiff.nu/_files/qprole/qproleday2101115.pdfPCI Pharmaceutical Consulting . ... •MHRA Compliance Report program and FDA ... probably get into an OOS](https://reader034.vdocuments.us/reader034/viewer/2022051407/5b0b13057f8b9aba628d41b6/html5/thumbnails/20.jpg)
Annex 16Batch release – pre-requisites
• QP discretion
• CAPA, investigations…
• And before any of that process mapping and risk assessment!
![Page 21: PCI Pharmaceutical Consulting - IFFiff.nu/_files/qprole/qproleday2101115.pdfPCI Pharmaceutical Consulting . ... •MHRA Compliance Report program and FDA ... probably get into an OOS](https://reader034.vdocuments.us/reader034/viewer/2022051407/5b0b13057f8b9aba628d41b6/html5/thumbnails/21.jpg)
Risk Assessment for Excipients
![Page 22: PCI Pharmaceutical Consulting - IFFiff.nu/_files/qprole/qproleday2101115.pdfPCI Pharmaceutical Consulting . ... •MHRA Compliance Report program and FDA ... probably get into an OOS](https://reader034.vdocuments.us/reader034/viewer/2022051407/5b0b13057f8b9aba628d41b6/html5/thumbnails/22.jpg)
What’s Troubling the Inspector 2015
• #1 Data integrity
• #2 Quality Culture (???)(attitude of most senior management??)leadership?
• #3 Quality Metrics
• #4 Drug Shortages
• #5 Supply chain and falsified medicines(although ties in with #1…closely)
![Page 23: PCI Pharmaceutical Consulting - IFFiff.nu/_files/qprole/qproleday2101115.pdfPCI Pharmaceutical Consulting . ... •MHRA Compliance Report program and FDA ... probably get into an OOS](https://reader034.vdocuments.us/reader034/viewer/2022051407/5b0b13057f8b9aba628d41b6/html5/thumbnails/23.jpg)
GMP / GDP Inspectors Working Group
![Page 24: PCI Pharmaceutical Consulting - IFFiff.nu/_files/qprole/qproleday2101115.pdfPCI Pharmaceutical Consulting . ... •MHRA Compliance Report program and FDA ... probably get into an OOS](https://reader034.vdocuments.us/reader034/viewer/2022051407/5b0b13057f8b9aba628d41b6/html5/thumbnails/24.jpg)
FDA Guidance Agenda 2015
![Page 25: PCI Pharmaceutical Consulting - IFFiff.nu/_files/qprole/qproleday2101115.pdfPCI Pharmaceutical Consulting . ... •MHRA Compliance Report program and FDA ... probably get into an OOS](https://reader034.vdocuments.us/reader034/viewer/2022051407/5b0b13057f8b9aba628d41b6/html5/thumbnails/25.jpg)
What changes in last 12 monthsEU GMPs
Part 1• Cap 2: Personnel• Cap 3: Premises and Equipt• Cap 5: Production• Cap 6: Quality Control• Cap 8: Complaints, Recalls
Part 2 APIsAnnex 1Annex 15 Annex 16Annex 17
Effective:• 16 Feb 2014• 01 Mar 2015• 01 Mar 2015• 01 Oct 2014• 01 Mar 2015
• 01 Sep 2014• Concept paper on revision• 01 Oct 2015• 01 April 2016• Draft out
![Page 26: PCI Pharmaceutical Consulting - IFFiff.nu/_files/qprole/qproleday2101115.pdfPCI Pharmaceutical Consulting . ... •MHRA Compliance Report program and FDA ... probably get into an OOS](https://reader034.vdocuments.us/reader034/viewer/2022051407/5b0b13057f8b9aba628d41b6/html5/thumbnails/26.jpg)
2 - Personnel
• Effective Feb 2014
• Changes:
– Integrate principles of quality system i.e. ICH Q10
– Leadership and quality culture /metrics(come to it a little later on)
![Page 27: PCI Pharmaceutical Consulting - IFFiff.nu/_files/qprole/qproleday2101115.pdfPCI Pharmaceutical Consulting . ... •MHRA Compliance Report program and FDA ... probably get into an OOS](https://reader034.vdocuments.us/reader034/viewer/2022051407/5b0b13057f8b9aba628d41b6/html5/thumbnails/27.jpg)
3 – Premises and Equipment
3.6 as part of improved guidance on prevention of cross-contamination involving Cap 5
![Page 28: PCI Pharmaceutical Consulting - IFFiff.nu/_files/qprole/qproleday2101115.pdfPCI Pharmaceutical Consulting . ... •MHRA Compliance Report program and FDA ... probably get into an OOS](https://reader034.vdocuments.us/reader034/viewer/2022051407/5b0b13057f8b9aba628d41b6/html5/thumbnails/28.jpg)
5 - Production
![Page 29: PCI Pharmaceutical Consulting - IFFiff.nu/_files/qprole/qproleday2101115.pdfPCI Pharmaceutical Consulting . ... •MHRA Compliance Report program and FDA ... probably get into an OOS](https://reader034.vdocuments.us/reader034/viewer/2022051407/5b0b13057f8b9aba628d41b6/html5/thumbnails/29.jpg)
6 – Quality Control
![Page 30: PCI Pharmaceutical Consulting - IFFiff.nu/_files/qprole/qproleday2101115.pdfPCI Pharmaceutical Consulting . ... •MHRA Compliance Report program and FDA ... probably get into an OOS](https://reader034.vdocuments.us/reader034/viewer/2022051407/5b0b13057f8b9aba628d41b6/html5/thumbnails/30.jpg)
8 – Complaints, Quality Defects and Product Recalls
![Page 31: PCI Pharmaceutical Consulting - IFFiff.nu/_files/qprole/qproleday2101115.pdfPCI Pharmaceutical Consulting . ... •MHRA Compliance Report program and FDA ... probably get into an OOS](https://reader034.vdocuments.us/reader034/viewer/2022051407/5b0b13057f8b9aba628d41b6/html5/thumbnails/31.jpg)
Annex 15 Validation
![Page 32: PCI Pharmaceutical Consulting - IFFiff.nu/_files/qprole/qproleday2101115.pdfPCI Pharmaceutical Consulting . ... •MHRA Compliance Report program and FDA ... probably get into an OOS](https://reader034.vdocuments.us/reader034/viewer/2022051407/5b0b13057f8b9aba628d41b6/html5/thumbnails/32.jpg)
Annex 17: Real TimeRelease Testing RTRT
32
![Page 33: PCI Pharmaceutical Consulting - IFFiff.nu/_files/qprole/qproleday2101115.pdfPCI Pharmaceutical Consulting . ... •MHRA Compliance Report program and FDA ... probably get into an OOS](https://reader034.vdocuments.us/reader034/viewer/2022051407/5b0b13057f8b9aba628d41b6/html5/thumbnails/33.jpg)
Part 2 – Active Substance / API
![Page 34: PCI Pharmaceutical Consulting - IFFiff.nu/_files/qprole/qproleday2101115.pdfPCI Pharmaceutical Consulting . ... •MHRA Compliance Report program and FDA ... probably get into an OOS](https://reader034.vdocuments.us/reader034/viewer/2022051407/5b0b13057f8b9aba628d41b6/html5/thumbnails/34.jpg)
Other
• US GMPs: 21CFR parts 210, 211, part 11 and part 820
• FDA guidances:
– Draft guidance on quality metrics
– Quality system guidance vs ICH Q8, 9, 10
– Process validation guidance
– Contract Manufacture
![Page 35: PCI Pharmaceutical Consulting - IFFiff.nu/_files/qprole/qproleday2101115.pdfPCI Pharmaceutical Consulting . ... •MHRA Compliance Report program and FDA ... probably get into an OOS](https://reader034.vdocuments.us/reader034/viewer/2022051407/5b0b13057f8b9aba628d41b6/html5/thumbnails/35.jpg)
Other
• MHRA Compliance Report program and FDA on quality metrics
• WHO Guidances
• PIC/s Guidances
• USP, European Pharmacopoeia
• Pulling together the threads and staying updated
![Page 36: PCI Pharmaceutical Consulting - IFFiff.nu/_files/qprole/qproleday2101115.pdfPCI Pharmaceutical Consulting . ... •MHRA Compliance Report program and FDA ... probably get into an OOS](https://reader034.vdocuments.us/reader034/viewer/2022051407/5b0b13057f8b9aba628d41b6/html5/thumbnails/36.jpg)
Hot Topics – Data Integrity
![Page 37: PCI Pharmaceutical Consulting - IFFiff.nu/_files/qprole/qproleday2101115.pdfPCI Pharmaceutical Consulting . ... •MHRA Compliance Report program and FDA ... probably get into an OOS](https://reader034.vdocuments.us/reader034/viewer/2022051407/5b0b13057f8b9aba628d41b6/html5/thumbnails/37.jpg)
Data Integrity – does your company have a data governance policy?
![Page 38: PCI Pharmaceutical Consulting - IFFiff.nu/_files/qprole/qproleday2101115.pdfPCI Pharmaceutical Consulting . ... •MHRA Compliance Report program and FDA ... probably get into an OOS](https://reader034.vdocuments.us/reader034/viewer/2022051407/5b0b13057f8b9aba628d41b6/html5/thumbnails/38.jpg)
What is Quality
• Meeting requirements – all of them all the time and that means defining the requirements
• Annex 16 defines requirements for batch certification and release
![Page 39: PCI Pharmaceutical Consulting - IFFiff.nu/_files/qprole/qproleday2101115.pdfPCI Pharmaceutical Consulting . ... •MHRA Compliance Report program and FDA ... probably get into an OOS](https://reader034.vdocuments.us/reader034/viewer/2022051407/5b0b13057f8b9aba628d41b6/html5/thumbnails/39.jpg)
Waivers
• the act of intentionally [and voluntarily] relinquishing or abandoning a known right, claim, or privilege
• So a “planned” deviation or “temporary” change or “special” release is a waiver of “quality” which is meeting requirements (all of them all the time)
![Page 40: PCI Pharmaceutical Consulting - IFFiff.nu/_files/qprole/qproleday2101115.pdfPCI Pharmaceutical Consulting . ... •MHRA Compliance Report program and FDA ... probably get into an OOS](https://reader034.vdocuments.us/reader034/viewer/2022051407/5b0b13057f8b9aba628d41b6/html5/thumbnails/40.jpg)
Have you Heard About…ISO 9001:2015?
![Page 41: PCI Pharmaceutical Consulting - IFFiff.nu/_files/qprole/qproleday2101115.pdfPCI Pharmaceutical Consulting . ... •MHRA Compliance Report program and FDA ... probably get into an OOS](https://reader034.vdocuments.us/reader034/viewer/2022051407/5b0b13057f8b9aba628d41b6/html5/thumbnails/41.jpg)
What is the differenceProduct control Process control
![Page 42: PCI Pharmaceutical Consulting - IFFiff.nu/_files/qprole/qproleday2101115.pdfPCI Pharmaceutical Consulting . ... •MHRA Compliance Report program and FDA ... probably get into an OOS](https://reader034.vdocuments.us/reader034/viewer/2022051407/5b0b13057f8b9aba628d41b6/html5/thumbnails/42.jpg)
Product vs Process Control
Product
• Is controlled at the end of the process and you can do nothing about it – you have already made the quality –so you test and if it is ok –release and if it is not ok –you SHOULD reject but you probably get into an OOS fight
Process
• Is controlled through understanding where the variability is and controlling critical process parameters such that all three cakes come out the same even when baked by three different students in three different ovens
![Page 43: PCI Pharmaceutical Consulting - IFFiff.nu/_files/qprole/qproleday2101115.pdfPCI Pharmaceutical Consulting . ... •MHRA Compliance Report program and FDA ... probably get into an OOS](https://reader034.vdocuments.us/reader034/viewer/2022051407/5b0b13057f8b9aba628d41b6/html5/thumbnails/43.jpg)
“My bread is fresh and tasty”
Quality control: the process of
producing the product (or service) with
the intent of eliminating problems that
might result in defects
The use of techniques and activities to
achieve, sustain and improve the
quality of a product
![Page 44: PCI Pharmaceutical Consulting - IFFiff.nu/_files/qprole/qproleday2101115.pdfPCI Pharmaceutical Consulting . ... •MHRA Compliance Report program and FDA ... probably get into an OOS](https://reader034.vdocuments.us/reader034/viewer/2022051407/5b0b13057f8b9aba628d41b6/html5/thumbnails/44.jpg)
Where does QP Responsibility Fit…?Certification and Release
44
![Page 45: PCI Pharmaceutical Consulting - IFFiff.nu/_files/qprole/qproleday2101115.pdfPCI Pharmaceutical Consulting . ... •MHRA Compliance Report program and FDA ... probably get into an OOS](https://reader034.vdocuments.us/reader034/viewer/2022051407/5b0b13057f8b9aba628d41b6/html5/thumbnails/45.jpg)
CPPs and CQAs
(Critical) Quality Attribute (CQA):• A physical, chemical, biological or microbiological property or
characteristic that should be within an appropriate limit, range, or distribution to ensure the desired product quality
[= safety, efficacy, performance](Critical) Process Parameter (CPP):• A process parameter whose variability has an impact on a
critical quality attribute and therefore should be monitored or controlled to ensure the process produces the desired quality
45
![Page 46: PCI Pharmaceutical Consulting - IFFiff.nu/_files/qprole/qproleday2101115.pdfPCI Pharmaceutical Consulting . ... •MHRA Compliance Report program and FDA ... probably get into an OOS](https://reader034.vdocuments.us/reader034/viewer/2022051407/5b0b13057f8b9aba628d41b6/html5/thumbnails/46.jpg)
46
People
Equipment
Measurement
Process
Materials
Environment
I
N
P
U
T
S
(X)
y = ƒ(x)
OUTPUT
y
Inputs to the process
control variabilityof the Output
Observation
Ind
ivid
ua
l V
alu
e
4038363432302826242220
120
115
110
105
100
95
90
_X=102.37
UCL=116.68
LCL=88.05
I Chart
Observation
Ind
ivid
ua
l V
alu
e
6058565452504846444240
115
110
105
100
95
90
85
80
_X=97.94
UCL=112.65
LCL=83.23
I Chart
Observation
Ind
ivid
ua
l V
alu
e
8078767472706866646260
115
110
105
100
95
90
_X=99.63
UCL=111.55
LCL=87.71
I Chart
Observation
Ind
ivid
ua
l V
alu
e
10098969492908886848280
110
105
100
95
90
85
_X=98.76
UCL=111.17
LCL=86.35
I Chart
Observation
Ind
ivid
ua
l V
alu
e
6058565452504846444240
115
110
105
100
95
90
85
80
_X=97.94
UCL=112.65
LCL=83.23
I Chart
Observation
Ind
ivid
ua
l V
alu
e
8078767472706866646260
115
110
105
100
95
90
_X=99.63
UCL=111.55
LCL=87.71
I Chart
Observation
Ind
ivid
ua
l V
alu
e
9181716151413121111
115
110
105
100
95
90
85
_X=99.95
UCL=114.17
LCL=85.72
I Chart
Adapted from slide by Moheb Naser, When at FDA
CPPs affect CQAs: Reliable / PredictableKnown variation / Reduce Variation
46
![Page 47: PCI Pharmaceutical Consulting - IFFiff.nu/_files/qprole/qproleday2101115.pdfPCI Pharmaceutical Consulting . ... •MHRA Compliance Report program and FDA ... probably get into an OOS](https://reader034.vdocuments.us/reader034/viewer/2022051407/5b0b13057f8b9aba628d41b6/html5/thumbnails/47.jpg)
George Bernard Shaw
The only man I know who behaves sensibly is my
tailor - he takes my measurements anew each time
he sees me.
The rest go on with their old measurements and
expect me to fit them
![Page 48: PCI Pharmaceutical Consulting - IFFiff.nu/_files/qprole/qproleday2101115.pdfPCI Pharmaceutical Consulting . ... •MHRA Compliance Report program and FDA ... probably get into an OOS](https://reader034.vdocuments.us/reader034/viewer/2022051407/5b0b13057f8b9aba628d41b6/html5/thumbnails/48.jpg)
FDA Metrics
![Page 49: PCI Pharmaceutical Consulting - IFFiff.nu/_files/qprole/qproleday2101115.pdfPCI Pharmaceutical Consulting . ... •MHRA Compliance Report program and FDA ... probably get into an OOS](https://reader034.vdocuments.us/reader034/viewer/2022051407/5b0b13057f8b9aba628d41b6/html5/thumbnails/49.jpg)
FDA Optional Metrics Related to Quality Culture and Process Capability/Performance
![Page 50: PCI Pharmaceutical Consulting - IFFiff.nu/_files/qprole/qproleday2101115.pdfPCI Pharmaceutical Consulting . ... •MHRA Compliance Report program and FDA ... probably get into an OOS](https://reader034.vdocuments.us/reader034/viewer/2022051407/5b0b13057f8b9aba628d41b6/html5/thumbnails/50.jpg)
Optional metric #2
![Page 51: PCI Pharmaceutical Consulting - IFFiff.nu/_files/qprole/qproleday2101115.pdfPCI Pharmaceutical Consulting . ... •MHRA Compliance Report program and FDA ... probably get into an OOS](https://reader034.vdocuments.us/reader034/viewer/2022051407/5b0b13057f8b9aba628d41b6/html5/thumbnails/51.jpg)
Optional metric #2
![Page 52: PCI Pharmaceutical Consulting - IFFiff.nu/_files/qprole/qproleday2101115.pdfPCI Pharmaceutical Consulting . ... •MHRA Compliance Report program and FDA ... probably get into an OOS](https://reader034.vdocuments.us/reader034/viewer/2022051407/5b0b13057f8b9aba628d41b6/html5/thumbnails/52.jpg)
Optional metric #3
![Page 53: PCI Pharmaceutical Consulting - IFFiff.nu/_files/qprole/qproleday2101115.pdfPCI Pharmaceutical Consulting . ... •MHRA Compliance Report program and FDA ... probably get into an OOS](https://reader034.vdocuments.us/reader034/viewer/2022051407/5b0b13057f8b9aba628d41b6/html5/thumbnails/53.jpg)
What Quality Data Would Be Reported
![Page 54: PCI Pharmaceutical Consulting - IFFiff.nu/_files/qprole/qproleday2101115.pdfPCI Pharmaceutical Consulting . ... •MHRA Compliance Report program and FDA ... probably get into an OOS](https://reader034.vdocuments.us/reader034/viewer/2022051407/5b0b13057f8b9aba628d41b6/html5/thumbnails/54.jpg)
What Quality Data Would Be Reported
![Page 55: PCI Pharmaceutical Consulting - IFFiff.nu/_files/qprole/qproleday2101115.pdfPCI Pharmaceutical Consulting . ... •MHRA Compliance Report program and FDA ... probably get into an OOS](https://reader034.vdocuments.us/reader034/viewer/2022051407/5b0b13057f8b9aba628d41b6/html5/thumbnails/55.jpg)
Measurement is the basis of the Quality Process
• What do we measure
• What could we measure
• What should we measure
• What can we measure
![Page 56: PCI Pharmaceutical Consulting - IFFiff.nu/_files/qprole/qproleday2101115.pdfPCI Pharmaceutical Consulting . ... •MHRA Compliance Report program and FDA ... probably get into an OOS](https://reader034.vdocuments.us/reader034/viewer/2022051407/5b0b13057f8b9aba628d41b6/html5/thumbnails/56.jpg)
Data Collection Plans (Protocols)
What data NEEDS to be collected(if all data is important then none is important)
HOW should it be collected?
HOW should it be analyzed?
HOW should it be presented? And by who and to whom?
56
![Page 57: PCI Pharmaceutical Consulting - IFFiff.nu/_files/qprole/qproleday2101115.pdfPCI Pharmaceutical Consulting . ... •MHRA Compliance Report program and FDA ... probably get into an OOS](https://reader034.vdocuments.us/reader034/viewer/2022051407/5b0b13057f8b9aba628d41b6/html5/thumbnails/57.jpg)
How many metrics
• BE CAREFUL – if everything is important then nothing is important
![Page 58: PCI Pharmaceutical Consulting - IFFiff.nu/_files/qprole/qproleday2101115.pdfPCI Pharmaceutical Consulting . ... •MHRA Compliance Report program and FDA ... probably get into an OOS](https://reader034.vdocuments.us/reader034/viewer/2022051407/5b0b13057f8b9aba628d41b6/html5/thumbnails/58.jpg)
About Measurement
• “Measurement is the first step that leads to control and eventually to improvement
• If you can’t measure something, you can’t understand it
• If you can’t understand it, you can’t control it
• If you can’t control it, you can’t improve it.”
H. James Harrington
![Page 59: PCI Pharmaceutical Consulting - IFFiff.nu/_files/qprole/qproleday2101115.pdfPCI Pharmaceutical Consulting . ... •MHRA Compliance Report program and FDA ... probably get into an OOS](https://reader034.vdocuments.us/reader034/viewer/2022051407/5b0b13057f8b9aba628d41b6/html5/thumbnails/59.jpg)
Measureable…But Meaningful
• If a measurement matters at all, it is because it must have some conceivable effect on decisions and behavior
• If we can't identify a decision that could be affected by a proposed measurement and how it could change those decisions, then the measurement simply has no value
Douglas W. Hubbard, How to Measure Anything: Finding the Value of Intangibles in Business
![Page 60: PCI Pharmaceutical Consulting - IFFiff.nu/_files/qprole/qproleday2101115.pdfPCI Pharmaceutical Consulting . ... •MHRA Compliance Report program and FDA ... probably get into an OOS](https://reader034.vdocuments.us/reader034/viewer/2022051407/5b0b13057f8b9aba628d41b6/html5/thumbnails/60.jpg)
Data Collection Plans
• Who decides what data to collect?
• How do they make that decision?
• How do they COMMUNICATE the decision?(what are the tools)
• How do they educate for compliance with the data collection plan?
![Page 61: PCI Pharmaceutical Consulting - IFFiff.nu/_files/qprole/qproleday2101115.pdfPCI Pharmaceutical Consulting . ... •MHRA Compliance Report program and FDA ... probably get into an OOS](https://reader034.vdocuments.us/reader034/viewer/2022051407/5b0b13057f8b9aba628d41b6/html5/thumbnails/61.jpg)
The toolbox – Fabulous 14 Tools
• Process flow diagram• Cause and effect (fishbone)• Pareto chart• Check sheets• Location diagrams• Tally count• Time plot• Scatter diagram• Histogram• Stem and Leaf• Box and Whisper plot• Regression analysis• Control Chart• Conformance chart
![Page 62: PCI Pharmaceutical Consulting - IFFiff.nu/_files/qprole/qproleday2101115.pdfPCI Pharmaceutical Consulting . ... •MHRA Compliance Report program and FDA ... probably get into an OOS](https://reader034.vdocuments.us/reader034/viewer/2022051407/5b0b13057f8b9aba628d41b6/html5/thumbnails/62.jpg)
Dashboards
• Dashboards are reporting tools that consolidate and arrange numbers, metrics and sometimes scorecards on a single screen
• Usually tailored for a specific role
• Display metrics targeted for a single point of view or department
![Page 63: PCI Pharmaceutical Consulting - IFFiff.nu/_files/qprole/qproleday2101115.pdfPCI Pharmaceutical Consulting . ... •MHRA Compliance Report program and FDA ... probably get into an OOS](https://reader034.vdocuments.us/reader034/viewer/2022051407/5b0b13057f8b9aba628d41b6/html5/thumbnails/63.jpg)
Dashboards
![Page 64: PCI Pharmaceutical Consulting - IFFiff.nu/_files/qprole/qproleday2101115.pdfPCI Pharmaceutical Consulting . ... •MHRA Compliance Report program and FDA ... probably get into an OOS](https://reader034.vdocuments.us/reader034/viewer/2022051407/5b0b13057f8b9aba628d41b6/html5/thumbnails/64.jpg)
The Power of Walking the Floor
• Thoughts?
![Page 65: PCI Pharmaceutical Consulting - IFFiff.nu/_files/qprole/qproleday2101115.pdfPCI Pharmaceutical Consulting . ... •MHRA Compliance Report program and FDA ... probably get into an OOS](https://reader034.vdocuments.us/reader034/viewer/2022051407/5b0b13057f8b9aba628d41b6/html5/thumbnails/65.jpg)
The Power of Walking the Floor
• “You see but you do not observe”
• Just stand and watch a production operation and ask questions about what you see
• Talk to operators and LISTEN to their comments
• You must understand the processes you are certifying
![Page 66: PCI Pharmaceutical Consulting - IFFiff.nu/_files/qprole/qproleday2101115.pdfPCI Pharmaceutical Consulting . ... •MHRA Compliance Report program and FDA ... probably get into an OOS](https://reader034.vdocuments.us/reader034/viewer/2022051407/5b0b13057f8b9aba628d41b6/html5/thumbnails/66.jpg)
In Conclusion
• GMP isn’t enough even if “c”
• Keep it Simple:
– Define requirements
– Use Risk Management to identify risks and prevent them from happening
– Monitor and improve in a PDCA cycle
![Page 67: PCI Pharmaceutical Consulting - IFFiff.nu/_files/qprole/qproleday2101115.pdfPCI Pharmaceutical Consulting . ... •MHRA Compliance Report program and FDA ... probably get into an OOS](https://reader034.vdocuments.us/reader034/viewer/2022051407/5b0b13057f8b9aba628d41b6/html5/thumbnails/67.jpg)
In Conclusion
• Stay up to date…
• Stay cool, calm and collected
• Ask for and make sure you get data and information in order to make informed decisions
• Have process maps and regularly audit or have links in the chain audited by people you trust
• Investigate and participate in significant deviations, changes and quality defects / complaints
• Refuse to be brushed aside with an “it’s ok”
• Use RISK MANAGEMENT not just “take risks”